- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT03141710
Commercial Prebiotic Supplement Study
Effect of Prebiotic in Type 2 Diabetes (Diabetes and Health Study)
Previous work in 2015/16 has identified changes in the gut microbiota with prebiotic (Molkosan®) supplement. It report significant changes in metabolic health bio-markers and faecal SCFA profile in 18 health adult subjects consuming 20 ml of product twice a day. Improvement in fasting metabolic parameters was observed flowing the intervention period. A reduction on Total Cholesterol, Glucose, Triglycerides and Insulin was observed.
In this study, a lower dose (20ml/d) in subjects with type 2 diabetes will be examed, over an extended period of time (12 week period) to match the profile of the intended consumer and provide preliminary data to support a larger multi-centre trial.
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Detailní popis
The study will be conducted in males and females with type 2 diabetes managed by diet and lifestyle alone.
The participants who meet the inclusion and exclusion criteria of the study will attend a screening visit where they will complete a medical screening and sign the consent form for participation in the study. Participates will visit the Human Nutrition Unit at the Rowett Institute to provide samples at week 0 (baseline), week 6 and week 12.
Participants' height, weight, and blood pressure will also be recorded. The investigators will measure HbA1c by a finger prick blood sample to confirm whether participants are a prediabetic or type 2 diabetic subjects. A 3-day weighed intake food diary will be completed during the initial washout period (minimum of 7 days) of the study in order to note their normal eating habits. No probiotic or prebiotics to be consumed during washout period and study period.
During the study periods, participants will take 20ml of prebiotic daily over the 12 consecutive weeks.
For the study visits, each participant will undergo, on two separated occasions, an OGTT, with and without the product at week 0 (to assess acute effects, prior to chronic ingestion) and at week 12 (to assess acute effects after chronic ingestion). The two OGTTs (with and without test product) will be separated by a period of 48 hr. Thus, each participant will have four OGTTs during the study. To minimise systematic errors, one half of the participants will start with the test product OGTT and the other half will start without product OGTT. The starting order will be determined randomly. Six blood samples will be collected during the course of 3 hours (0, 30, 60, 90,120 and 180 min) using a cannulation after consuming 75 g of Polycal liquid (glucose load). Together with OGTT, breath samples will be taken every 30 min for measuring hydrogen and methane.
Only one fasted blood sample will be taken at week 6 (OGTT will not be performed at week 6).
Finger prick blood sample will be taken at week 12 to monitor for changes in HbA1c levels after prebiotic supplement.
Plasma samples will be collected from all blood samples from OGTTs and week 6 blood sample. Plasma glucose and lipid profiles (total cholesterol, HDL, LDL and triglycerides) will be measured by KONI analysis at the University of Aberdeen. Insulin will be measured by ELISA by researchers. All the plasma samples which are taken before and after taking the prebiotic supplement also be analysed for GLP-1, GIP, c-peptide and glucagon analysis by luminex assay.
GLP-1 and GIP are incretins which are produced in the intestinal mucosa and are normally secreted when food is eaten in order to reduce glycaemic exclusion by causing an increase in insulin secretion. These incretins are involved in the early stage of the insulin secretory response however the plasma insulin response is also influenced by hepatic insulin extraction which GLP-1 and GIP measurement cannot determine, therefore to optimise this, C-peptide will be also measured in this study.
All the data will be compared before and after supplementation and values are presented by means ± standard deviations.
From the faecal samples, the SCFA content of the samples to be determined by capillary gas chromatography. SCFA to be quantified against authentic standards of acetate, propionate, butyrate, valerate and the branched chain fatty acids iso-butyrate and iso-valerate. The lower limit for reliable detection of each product is 0.2 mM. DNA to be extracted at University of Aberdeen using the FastDNA spin kit for faeces following the manufacturer's instructions and quantitative PCR (qPCR). Samples and standards are prepared in 96 well plate format, enabling the use of a multichannel pipettes for setting up the running plate. PCR primer sets and amplification conditions are as described in previous studies.
The complete dataset will be analysed and values will be presented as a mean value and standard deviation. Then the baseline value and the value after supplementation (at 6 and 12 weeks) will be compared. Statistically significantly differences will be calculated by statistician with power calculate.
Typ studie
Zápis (Očekávaný)
Fáze
- Nelze použít
Kontakty a umístění
Studijní místa
-
-
-
Aberdeen, Spojené království, AB25 2ZD
- Nábor
- The Rowett Institute, Human Nutrition Unit
-
Kontakt:
- Alexandra M Johnstone, PhD
- Telefonní číslo: 00441224438614
- E-mail: alex.johnstone@abdn.ac.uk
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Impaired glucose tolerance (IGT, identified by HbA1c) or type 2 diabetes (lifestyle management; identified by HbA1c) age 18-65, with BMI 18-40 kg m-2, measured at screening visit.
Exclusion Criteria:
- Type 1 Diabetes, Severe gastrointestinal disorders (IBD), Kidney disease, Thromboembolic or coagulation disease, Hepatic disease, Alcohol or any other substance abuse, Eating disorders, Unregulated thyroid disease, Antibiotic use within the last 3 months, including proscribed and prescribed use. Current probiotic use or prebiotic use. Medication for glucose regulation. Female with breast feeding.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Jiný
- Přidělení: N/A
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
---|---|
Experimentální: 12 type 2 diabetes patients
Long-term dietary (12 weeks) intervention of 20ml of prebiotic per day
|
12 volunteers will take 20ml of prebiotic per day for 12 weeks
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Change of oral glucose tolerance test (OGTT)
Časové okno: At baseline and 12 weeks prebiotic consumption
|
Six blood samples will be collected during the course of 3 hours (0, 30, 60, 90,120 and 180 min) using a cannulation after consuming 75 g of Polycal liquid (glucose load).
Plasma glucose level will be measured by KONI analysis and
|
At baseline and 12 weeks prebiotic consumption
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Change of insulin levels
Časové okno: At baseline, 6 weeks and 12 weeks prebiotic consumption
|
Six blood samples will be collected during the course of 3 hours (0, 30, 60, 90,120 and 180 min) using a cannulation after consuming 75 g of Polycal liquid (glucose load).
insulin level will be measured by luminex assay.
|
At baseline, 6 weeks and 12 weeks prebiotic consumption
|
HbA1c measured by Alere Afinion™ AS100 Analyzer
Časové okno: At baseline and 12 weeks prebiotic consumption
|
The term HbA1c refers to glycated haemoglobin. It develops when haemoglobin, a protein within red blood cells that carries oxygen throughout the body. By measuring glycated haemoglobin (HbA1c) can indicate blood sugar levels. Finger prick method will be introduced to collect the small amount of blood samples into the Alere Afinion™ AS100 Analyzer cartridge. Insert cartridge to the machine to read the data. Inclusion criteria will be the levels above 6 % (42mmol/mol). We will also measure HbA1c at 12 week to monitor for changes. |
At baseline and 12 weeks prebiotic consumption
|
Change of BMI (kg/m^2) measurement
Časové okno: At baseline and 12 weeks prebiotic consumption
|
Weight or Body Mass is defined as the quantity of matter in the body, measured by weight (kg) i.e. the force that matter exerts under standard gravitational effect.
Height (m) will be recorded for conjunction with weight measurements to calculate Body Mass Index (BMI) values.
|
At baseline and 12 weeks prebiotic consumption
|
Change of Total Cholesterol levels
Časové okno: At baseline, 6 weeks and 12 weeks prebiotic consumption
|
Total cholesterol (HDL and LDL -Cholesterols) will be measured by KONI analysis at University of Aberdeen.
Separately measured HDL- and LDL-cholesterols levels will be combined for total cholesterol levels.
|
At baseline, 6 weeks and 12 weeks prebiotic consumption
|
Change of GLP-1 levels
Časové okno: At baseline, 6 weeks and 12 weeks prebiotic consumption
|
The incretin hormones, glucagon-like peptide-1 (GLP-1) secretion, contributes to glucose intolerance.
GLP-1 levels will be measured by luminex assay.
|
At baseline, 6 weeks and 12 weeks prebiotic consumption
|
Change of GIP levels
Časové okno: At baseline, 6 weeks and 12 weeks prebiotic consumption
|
Glucose-dependent insulinotropic polypeptide (GIP) is potentiate the insulin response to nutrients.
Insulinotropic capacity of GIP is markedly diminished in type 2 diabetes.
Incretin hormone GIP will be measured by luminex assay.
|
At baseline, 6 weeks and 12 weeks prebiotic consumption
|
Change of triglyceride levels
Časové okno: At baseline, 6 weeks and 12 weeks prebiotic consumption
|
Triglyceride levels will be measured for identifying the lipid profiles.
Triglyceride will be measured by KONI analysis.
|
At baseline, 6 weeks and 12 weeks prebiotic consumption
|
Change of C-peptide levels
Časové okno: At baseline, 6 weeks and 12 weeks prebiotic consumption
|
C-peptide are involved to hepatic insulin extraction.
C-peptide levels are measured by luminex assay.
|
At baseline, 6 weeks and 12 weeks prebiotic consumption
|
Change of glucagon levels
Časové okno: At baseline, 6 weeks and 12 weeks prebiotic consumption
|
Glucagon levels will be measured by luminex assay.
|
At baseline, 6 weeks and 12 weeks prebiotic consumption
|
Change of fermentation markers
Časové okno: At baseline and 12 weeks prebiotic consumption
|
Breath samples will be measured hydrogen and methane levels
|
At baseline and 12 weeks prebiotic consumption
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Vrchní vyšetřovatel: Alexandra M Johnstone, PhD, University of Aberdeen, The Rowett Institute
Publikace a užitečné odkazy
Obecné publikace
- Walker AW, Ince J, Duncan SH, Webster LM, Holtrop G, Ze X, Brown D, Stares MD, Scott P, Bergerat A, Louis P, McIntosh F, Johnstone AM, Lobley GE, Parkhill J, Flint HJ. Dominant and diet-responsive groups of bacteria within the human colonic microbiota. ISME J. 2011 Feb;5(2):220-30. doi: 10.1038/ismej.2010.118. Epub 2010 Aug 5.
- Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr. 1995 Jun;125(6):1401-12. doi: 10.1093/jn/125.6.1401.
- Kenteu B, Noubiap JJ, Etoa MC, Azabji-Kenfack M, Dehayem M, Sobngwi E. Acute glycaemic effects of co-trimoxazole at prophylactic dose in healthy adults. BMC Endocr Disord. 2016 Nov 15;16(1):62. doi: 10.1186/s12902-016-0142-6.
- Marathe CS, Rayner CK, Lange K, Bound M, Wishart J, Jones KL, Kahn SE, Horowitz M. Relationships of the early insulin secretory response and oral disposition index with gastric emptying in subjects with normal glucose tolerance. Physiol Rep. 2017 Feb;5(4):e13122. doi: 10.14814/phy2.13122. Epub 2017 Feb 27.
- Salonen A, Lahti L, Salojarvi J, Holtrop G, Korpela K, Duncan SH, Date P, Farquharson F, Johnstone AM, Lobley GE, Louis P, Flint HJ, de Vos WM. Impact of diet and individual variation on intestinal microbiota composition and fermentation products in obese men. ISME J. 2014 Nov;8(11):2218-30. doi: 10.1038/ismej.2014.63. Epub 2014 Apr 24.
- Yanagimachi T, Fujita Y, Takeda Y, Honjo J, Sakagami H, Kitsunai H, Takiyama Y, Abiko A, Makino Y, Kieffer TJ, Haneda M. Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects. Mol Metab. 2016 Dec 31;6(2):226-231. doi: 10.1016/j.molmet.2016.12.009. eCollection 2017 Feb.
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Očekávaný)
Dokončení studie (Očekávaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- Study 805
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Diabetes mellitus, typ 2
-
Hoffmann-La RocheDokončenoDiabetes 2. typu, Diabetes 1. typuRakousko, Spojené království
-
Services Hospital, LahoreDokončeno
-
Griffin HospitalCalifornia Walnut CommissionDokončenoDIABETES MELLITUS TYP 2Spojené státy
-
West China HospitalDokončeno
-
University of Roma La SapienzaNeznámýDiabetes Mellitus Typ 2 Reaktivita krevních destiček StatinItálie
-
Bristol-Myers SquibbDokončenoDiabetes, typ 2Spojené státy, Kanada, Mexiko, Portoriko, Austrálie, Polsko, Tchaj-wan
-
Universidade Federal de Ouro PretoDokončeno
-
Novo Nordisk A/SNáborDiabetes, typ 2Spojené státy, Indie, Španělsko, Polsko, Jižní Afrika, Bulharsko, Německo, Japonsko, Portoriko
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Churchill HospitalDokončenoDiabetes, typ 2Spojené království
-
Kyowa Kirin Co., Ltd.Dokončeno